After randomization of tumor-bearing mice into four groups (vehicle, anti-PD-L antibody [300 μg/body, once weekly], AZD1775 [60 mg/kg, 5 of 7 days, Q.D.], and AZD1775 plus anti-PD-L1 antibody [n = 10 per group]), we treated all cohorts for 3 weeks. This evidence concerns the gene CD274 and neoplasm.